Table 3.
Pharmacotherapy, ablation, embolization and receptor-targeted therapy in pan-NETs patients.
| Total | Treatment before surgery | Treatment inititated after surgery (median months, IQR) | Duration months (IQR) | Treament initiated in non-operated patients (median months, IQR) | Duration in non-operated patients, (median months IQR) | |
|---|---|---|---|---|---|---|
| Somatostatin analogs (n) | 31 | 3 (3 - 8 months) | 18 (49, 2-105) |
66 (21-98) | 12 (43, 21-106) | 43 (21–106) |
| Streptozotocin-5-Fluorouracil (n) | 9 | 1 | 7 (24, 18-102) | 9 (6-14) | 1 | 4 |
| Radiofrequency ablation (RF) (n) | 7 | 3 per-operativ | 3 (36, 27–57) | 1 | ||
| Temozolamide (n) | 5 | 4 | 1 | 6 | ||
| Peptide receptor-targeted radiotherapy (PRRT) (n) | 5 | 2 | 3 | |||
| Cisplatin-Etoposide (n) | 2 | 1 | 1 | 6 | ||
| Everolimus (n) | 3 | 1 | 1 | 3 | ||
| Interferon (n) | 3 | 3 | ||||
| Transarterial embolization, radioembolization (n) | 2 | 2 |
Thirty-one were treated with somatostatin analogs, three of these patients were also treated with interferon, three with everolimus, two with temozolomide, and five with peptide receptor-targeted radiotherapy (PRRT). Other treatments according to the table, see text for details.